This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Asterias Biotherapeutics, Inc. Files Registration Statement For Underwritten Public Offering

Asterias Biotherapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE MKT: BTX), announced today that Asterias has filed a registration statement with the Securities and Exchange Commission for an underwritten public offering of up to $15,000,000 of units with each unit consisting of one share of Series B common stock and one redemption right. The shares of Series B common stock and redemption rights will immediately be freely tradable as separate securities. The number of units to be sold and the price range for the proposed offering have not yet been determined.

The offering will be made through Burrill Securities LLC.

Asterias plans to use the net proceeds of the offering to fund its product development programs and for working capital. Asterias intends to apply to list the Series B common stock on the NYSE MKT under the symbol “AST”.

Each redemption right will entitle the holder to sell a share of common stock to Asterias during a redemption period that will commence 30 days prior to the third anniversary of the closing of the offering and that will end on that third anniversary date. If a share is redeemed through the exercise of a redemption right, Asterias will pay the shareholder either an amount of cash, or common shares, no par value, of its parent company BioTime, Inc. (“BioTime”) with a value equal to the initial public offering price of the units, or a combination of cash and BioTime common shares. The decision whether to pay the redemption price in cash or BioTime shares or a combination of cash and shares will be made by Asterias in its discretion. The redemption rights will expire on the earlier of (a) the third anniversary of the closing of the offering, and (b) the earliest date, if any, on which the closing price of the Asterias common stock as reported on a national securities exchange, or the OTC Bulletin Board, has been at least 150% of the redemption price for 10 consecutive trading days.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,024.06 +183.54 1.03%
S&P 500 2,108.29 +22.78 1.09%
NASDAQ 5,005.3910 +63.9670 1.29%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs